Liu Tianlin, Tuo Jingtang, Wei Qianjie, Sun Xiuwei, Zhao Haochen, Zhao Xiaochen, Qu Min
Department of Anesthesiology, Cangzhou Central Hospital, Cangzhou, People's Republic of China.
Int J Gen Med. 2022 Jul 9;15:6105-6113. doi: 10.2147/IJGM.S370237. eCollection 2022.
The aim of the study was to determine whether perioperative dexmedetomidine administration can improve postoperative delirium in elderly patients undergoing oral and maxillofacial surgery.
This was a prospective double-blind randomized controlled clinical trial conducted in Cangzhou Central Hospital from December 2021 to March 2022. Patients aged 65 and older underwent oral and maxillofacial surgery under general anesthesia. Eligible patients were randomly assigned to dexmedetomidine or control group. Dexmedetomidine was injected intravenously from 10 min before induction of anesthesia to 30 min before the end of surgery in dexmedetomidine group, while patients in the control group were given normal saline at the same rate during the same time period. The primary measurement indicators were the incidence and duration of delirium in the first five days after surgery. The secondary measurement indicators were Visual Analogue Score (VAS) for the first 24 hours following surgery, subjective sleep quality score within 24 hours postoperatively and intraoperative adverse reactions.
One hundred and twenty patients were randomly assigned. Baseline characteristics were similar between two groups. The incidence and duration of postoperative delirium did not differ statistically between two groups (all P > 0.05). Compared with control group, VAS scores in dexmedetomidine group were significantly lower at 6, 12, and 24 hours after surgery (all P < 0.05); moreover, Richards-Campbell Sleep Questionnaire (RCSQ) results were significantly improved 1 day after surgery in dexmedetomidine group (P < 0.05). Dexmedetomidine-related adverse reactions were similar in both groups (P > 0.05).
Intravenous infusion of dexmedetomidine 10 min before induction of anesthesia to half an hour before the end of surgery did not improve postoperative delirium in elderly patients undergoing oral and maxillofacial surgery; however, dexmedetomidine may be associated with decreased postoperative pain and improved postoperative sleep quality.
本研究旨在确定围手术期给予右美托咪定是否能改善接受口腔颌面外科手术的老年患者术后谵妄。
这是一项于2021年12月至2022年3月在沧州市中心医院进行的前瞻性双盲随机对照临床试验。65岁及以上的患者在全身麻醉下接受口腔颌面外科手术。符合条件的患者被随机分配至右美托咪定组或对照组。右美托咪定组在麻醉诱导前10分钟至手术结束前30分钟静脉注射右美托咪定,而对照组患者在同一时间段内以相同速率给予生理盐水。主要测量指标为术后前五天谵妄的发生率和持续时间。次要测量指标为术后24小时内的视觉模拟评分(VAS)、术后24小时内的主观睡眠质量评分以及术中不良反应。
120例患者被随机分配。两组的基线特征相似。两组术后谵妄的发生率和持续时间在统计学上无差异(所有P>0.05)。与对照组相比,右美托咪定组术后6、12和24小时的VAS评分显著更低(所有P<0.05);此外,右美托咪定组术后1天的理查兹 - 坎贝尔睡眠问卷(RCSQ)结果显著改善(P<0.05)。两组中与右美托咪定相关的不良反应相似(P>0.05)。
在麻醉诱导前10分钟至手术结束前半小时静脉输注右美托咪定并不能改善接受口腔颌面外科手术的老年患者术后谵妄;然而,右美托咪定可能与术后疼痛减轻和术后睡眠质量改善有关。